Novartis Profit Falls as Generic Drugs Cut Into Sales
Swiss drugmaker Novartis reported falling profits and sales as cheaper generic versions of its medicines eat into business. The company's net sales dropped 1% to $13.11 billion, hurt mainly by generic competition for Entresto, its top-selling heart drug.
Novartis AG, one of the world's largest pharmaceutical companies, saw its first-quarter profits miss expectations as generic drug competition hurt sales of key medicines.
The Swiss company's net sales fell 1% year-over-year to $13.11 billion. The biggest hit came from generic competition against Entresto, Novartis's blockbuster heart failure drug that has been one of its top money-makers.
Generic drugs are copies of brand-name medicines that become available after patents expire. They typically cost 80-90% less than the original, creating intense price pressure for pharmaceutical companies.
Novartis said "U.S. generic erosion" was a major headwind to its business. Higher research and development costs also weighed on the company's operating income during the quarter.
The company has forecast that profits will continue declining this year as more of its drugs face generic competition. This follows a broader trend affecting major pharmaceutical companies as key patents expire.
When drug patents expire, cheaper generic versions flood the market, forcing prices down. This affects drug company profits and can impact future research spending on new medicines that patients depend on.
Watch for Novartis's next quarterly results and any announcements about new drug approvals to replace lost revenue from generic competition.
Was this article helpful?
0 people found this helpful